Effectiveness and tolerability of second-line treatment with vildagliptin versus other oral drugs for type 2 diabetes in a real-world setting in the Middle East: results from the EDGE study

• Published in: Vascular health and risk management 2015-01, Vol.11 (default), p.149-155
• Main Authors: Saab, Charles, Al-Saber, Feryal A, Haddad, Jihad, Jallo, Mahir Khalil, Steitieh, Habib, Bader, Giovanni, Ibrahim, Mohamed
• Format: Article
• Language: English
• Subjects: Adamantane - administration & dosage; Adamantane - adverse effects; Adamantane - analogs & derivatives; Adult; Antidiabetics; Biomarkers - blood; Blood Glucose - drug effects; Blood Glucose - metabolism; Care and treatment; Clinical medicine; Clinical trials; Developing countries; Diabetes; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; dipeptidyl peptidase-4; Dipeptidyl-Peptidase IV Inhibitors - administration & dosage; Dipeptidyl-Peptidase IV Inhibitors - adverse effects; Drug dosages; Drug therapy; Drug Therapy, Combination; Endocrinology; Female; Glycated Hemoglobin A - metabolism; Hospitals; Humans; Hypoglycemia; Hypoglycemic agents; Internal medicine; LDCs; Logistic Models; Male; Middle Aged; Middle East; Middle East - epidemiology; Nitriles - administration & dosage; Nitriles - adverse effects; Odds Ratio; oral antidiabetic drugs; Original Research; Patient outcomes; Patients; Peptides; Prevalence; Pyrrolidines - administration & dosage; Pyrrolidines - adverse effects; Ramadan; real world; Systematic review; Time Factors; Treatment Outcome; Type 2 diabetes; type 2 diabetes mellitus; Vildagliptin
• ISSN: 1178-2048; 1176-6344; 1178-2048
• DOI: 10.2147/VHRM.S73703

Type 2 diabetes mellitus (T2DM) is a chronic progressive disease that requires treatment intensification with antihyperglycemic agents due to progressive deterioration of β-cell function. A large observational study of 45,868 patients with T2DM across 27 countries (EDGE) assessed the effectiveness and safety of vildagliptin as add-on to other oral antidiabetic drugs (OADs) versus other comparator OAD combinations. Here, we present results from the Middle East countries (Bahrain, Jordan, Kuwait, Lebanon, Oman, Palestine, and the United Arab Emirates). Patients inadequately controlled with OAD monotherapy were eligible after the add-on treatment was chosen by the physician based on clinical judgment and patient need. Patients were assigned to either vildagliptin or comparator OADs (sulfonylureas, thiazolidinediones, glinides, α-glucosidase inhibitors, or metformin, except incretin-based therapies) based on the add-on therapy. The primary endpoint was the proportion of patients achieving a glycated hemoglobin (HbA1c) reduction of >0.3% without peripheral edema, hypoglycemia, discontinuation due to a gastrointestinal event, or weight gain≥5%. One of the secondary endpoints was the proportion of patients achieving HbA1c